

BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

Adelina Vorperian, M.D.

Physician's and Surgeon's
Certificate No. C 50390

Case No.: 800-2018-042937

Respondent.


DECISION

The attached Stipulated Settlement is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on April 8, 2022.

IT IS SO ORDERED: March 10, 2022.

MEDICAL BOARD OF CALIFORNIA



Richard E. Thorp, M.D. , Chair
Panel B

1 ROB BONTA
Attorney General of California
2 JUDITH T. ALVARADO
Supervising Deputy Attorney General
3 TAN N. TRAN
Deputy Attorney General
4 State Bar No. 197775
300 South Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6535
6 Facsimile: (916) 731-2117
Attorneys for Complainant
7

8 **BEFORE THE**
9 **MEDICAL BOARD OF CALIFORNIA**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

13 **ADELINA VORPERIAN, M.D.**
14 **7341 Foothill Blvd., Suite 203**
Tujunga, CA 91042-2720
15 **Physician's and Surgeon's Certificate**
No. C 50390,

16 Respondent.
17

Case No. 800-2018-042937

OAH No. 2021030933

18 **STIPULATED SETTLEMENT AND**
19 **DISCIPLINARY ORDER**

20 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
entitled proceedings that the following matters are true:

21 **PARTIES**

22 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of
23 California (Board). He brought this action solely in his official capacity and is represented in this
24 matter by Rob Bonta, Attorney General of the State of California, by Tan N. Tran, Deputy
25 Attorney General.

26 2. Respondent Adelina Vorperian, M.D. (Respondent) is represented in this proceeding
27 by attorney Peter R. Osinoff, Esq., of Bonne Bridges Mueller O'Keefe & Nichols, 355 South
28 Grand Avenue, Suite 1750, Los Angeles, California 90071-1562.

1 3. On or about March 24, 2000, the Board issued Physician's and Surgeon's Certificate
2 No. C 50390 to Adelina Vorperian, M.D. (Respondent). The Physician's and Surgeon's
3 Certificate was in full force and effect at all times relevant to the charges brought in Accusation
4 No. 800-2018-042937, and will expire on June 30, 2023, unless renewed.

5 JURISDICTION

6 4. Accusation No. 800-2018-042937 was filed before the Board, and is currently
7 pending against Respondent. The Accusation and all other statutorily required documents were
8 properly served on Respondent on January 25, 2021. Respondent timely filed her Notice of
9 Defense contesting the Accusation.

10 5. A copy of Accusation No. 800-2018-042937 is attached as Exhibit A and
11 incorporated herein by reference.

12 ADVISEMENT AND WAIVERS

13 6. Respondent has carefully read, fully discussed with counsel, and understands the
14 charges and allegations in Accusation No. 800-2018-042937. Respondent has also carefully read,
15 fully discussed with her counsel, and understands the effects of this Stipulated Settlement and
16 Disciplinary Order.

17 7. Respondent is fully aware of her legal rights in this matter, including the right to a
18 hearing on the charges and allegations in the Accusation; the right to confront and cross-examine
19 the witnesses against her; the right to present evidence and to testify on her own behalf; the right
20 to the issuance of subpoenas to compel the attendance of witnesses and the production of
21 documents; the right to reconsideration and court review of an adverse decision; and all other
22 rights accorded by the California Administrative Procedure Act and other applicable laws.

23 8. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
24 every right set forth above.

25 CULPABILITY

26 9. Respondent understands that the charges and allegations in Accusation No. 800-2018-
27 042937, if proven at a hearing, constitute cause for imposing discipline upon her Physician's and
28 Surgeon's Certificate.

1 2. CONTROLLED SUBSTANCES - MAINTAIN RECORDS AND ACCESS TO
2 RECORDS AND INVENTORIES. Respondent shall maintain a record of all controlled
3 substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any
4 recommendation or approval which enables a patient or patient's primary caregiver to possess or
5 cultivate marijuana for the personal medical purposes of the patient within the meaning of Health
6 and Safety Code section 11362.5, during probation, showing all of the following: 1) the name and
7 address of the patient; 2) the date; 3) the character and quantity of controlled substances involved;
8 and 4) the indications and diagnosis for which the controlled substances were furnished.

9 Respondent shall keep these records in a separate file or ledger, in chronological order. All
10 records and any inventories of controlled substances shall be available for immediate inspection
11 and copying on the premises by the Board or its designee at all times during business hours and
12 shall be retained for the entire term of probation.

13 3. EDUCATION COURSE. Within 60 calendar days of the effective date of this
14 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee
15 for its prior approval educational program(s) or course(s) which shall not be less than 40 hours
16 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at
17 correcting any areas of deficient practice or knowledge and shall be Category I certified. The
18 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to
19 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the
20 completion of each course, the Board or its designee may administer an examination to test
21 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 65
22 hours of CME of which 40 hours were in satisfaction of this condition.

23 4. PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective
24 date of this Decision, Respondent shall enroll in a course in prescribing practices approved in
25 advance by the Board or its designee. Respondent shall provide the approved course provider
26 with any information and documents that the approved course provider may deem pertinent.
27 Respondent shall participate in and successfully complete the classroom component of the course
28 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully

1 complete any other component of the course within one (1) year of enrollment. The prescribing
2 practices course shall be at Respondent's expense and shall be in addition to the Continuing
3 Medical Education (CME) requirements for renewal of licensure.

4 A prescribing practices course taken after the acts that gave rise to the charges in the
5 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
6 or its designee, be accepted towards the fulfillment of this condition if the course would have
7 been approved by the Board or its designee had the course been taken after the effective date of
8 this Decision.

9 Respondent shall submit a certification of successful completion to the Board or its
10 designee not later than 15 calendar days after successfully completing the course, or not later than
11 15 calendar days after the effective date of the Decision, whichever is later.

12 5. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective
13 date of this Decision, Respondent shall enroll in a course in medical record keeping approved in
14 advance by the Board or its designee. Respondent shall provide the approved course provider
15 with any information and documents that the approved course provider may deem pertinent.
16 Respondent shall participate in and successfully complete the classroom component of the course
17 not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully
18 complete any other component of the course within one (1) year of enrollment. The medical
19 record keeping course shall be at Respondent's expense and shall be in addition to the Continuing
20 Medical Education (CME) requirements for renewal of licensure.

21 A medical record keeping course taken after the acts that gave rise to the charges in the
22 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
23 or its designee, be accepted towards the fulfillment of this condition if the course would have
24 been approved by the Board or its designee had the course been taken after the effective date of
25 this Decision.

26 Respondent shall submit a certification of successful completion to the Board or its
27 designee not later than 15 calendar days after successfully completing the course, or not later than
28 15 calendar days after the effective date of the Decision, whichever is later.

1 6. PROFESSIONALISM PROGRAM (ETHICS COURSE). Within 60 calendar days of
2 the effective date of this Decision, Respondent shall enroll in a professionalism program, that
3 meets the requirements of Title 16, California Code of Regulations (CCR) section 1358.1.
4 Respondent shall participate in and successfully complete that program. Respondent shall
5 provide any information and documents that the program may deem pertinent. Respondent shall
6 successfully complete the classroom component of the program not later than six (6) months after
7 Respondent's initial enrollment, and the longitudinal component of the program not later than the
8 time specified by the program, but no later than one (1) year after attending the classroom
9 component. The professionalism program shall be at Respondent's expense and shall be in
10 addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

11 A professionalism program taken after the acts that gave rise to the charges in the
12 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board
13 or its designee, be accepted towards the fulfillment of this condition if the program would have
14 been approved by the Board or its designee had the program been taken after the effective date of
15 this Decision.

16 Respondent shall submit a certification of successful completion to the Board or its
17 designee not later than 15 calendar days after successfully completing the program or not later
18 than 15 calendar days after the effective date of the Decision, whichever is later.

19 7. MONITORING - PRACTICE. Within 30 calendar days of the effective date of this
20 Decision, Respondent shall submit to the Board or its designee for prior approval as a practice
21 monitor(s), the name and qualifications of one or more licensed physicians and surgeons whose
22 licenses are valid and in good standing, and who are preferably American Board of Medical
23 Specialties (ABMS) certified. A monitor shall have no prior or current business or personal
24 relationship with Respondent, or other relationship that could reasonably be expected to
25 compromise the ability of the monitor to render fair and unbiased reports to the Board, including
26 but not limited to any form of bartering, shall be in Respondent's field of practice, and must agree
27 to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

28 The Board or its designee shall provide the approved monitor with copies of the Decision(s)

1 and Accusation(s), and a proposed monitoring plan. Within 15 calendar days of receipt of the
2 Decision(s), Accusation(s), and proposed monitoring plan, the monitor shall submit a signed
3 statement that the monitor has read the Decision(s) and Accusation(s), fully understands the role
4 of a monitor, and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees
5 with the proposed monitoring plan, the monitor shall submit a revised monitoring plan with the
6 signed statement for approval by the Board or its designee.

7 Within 60 calendar days of the effective date of this Decision, and continuing throughout
8 probation, Respondent's practice shall be monitored by the approved monitor. Respondent shall
9 make all records available for immediate inspection and copying on the premises by the monitor
10 at all times during business hours and shall retain the records for the entire term of probation.

11 If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective
12 date of this Decision, Respondent shall receive a notification from the Board or its designee to
13 cease the practice of medicine within three (3) calendar days after being so notified. Respondent
14 shall cease the practice of medicine until a monitor is approved to provide monitoring
15 responsibility.

16 The monitor(s) shall submit a quarterly written report to the Board or its designee which
17 includes an evaluation of Respondent's performance, indicating whether Respondent's practices
18 are within the standards of practice of medicine, and whether Respondent is practicing medicine
19 safely, billing appropriately or both. It shall be the sole responsibility of Respondent to ensure
20 that the monitor submits the quarterly written reports to the Board or its designee within 10
21 calendar days after the end of the preceding quarter.

22 If the monitor resigns or is no longer available, Respondent shall, within 5 calendar days of
23 such resignation or unavailability, submit to the Board or its designee, for prior approval, the
24 name and qualifications of a replacement monitor who will be assuming that responsibility within
25 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60
26 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a
27 notification from the Board or its designee to cease the practice of medicine within three (3)
28 calendar days after being so notified. Respondent shall cease the practice of medicine until a

1 replacement monitor is approved and assumes monitoring responsibility.

2 In lieu of a monitor, Respondent may participate in a professional enhancement program
3 approved in advance by the Board or its designee that includes, at minimum, quarterly chart
4 review, semi-annual practice assessment, and semi-annual review of professional growth and
5 education. Respondent shall participate in the professional enhancement program at Respondent's
6 expense during the term of probation.

7 8. NOTIFICATION. Within seven (7) days of the effective date of this Decision, the
8 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the
9 Chief Executive Officer at every hospital where privileges or membership are extended to
10 Respondent, at any other facility where Respondent engages in the practice of medicine,
11 including all physician and locum tenens registries or other similar agencies, and to the Chief
12 Executive Officer at every insurance carrier which extends malpractice insurance coverage to
13 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15
14 calendar days.

15 This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

16 9. SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE
17 NURSES. During probation, Respondent is prohibited from supervising physician assistants and
18 advanced practice nurses.

19 10. OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules
20 governing the practice of medicine in California and remain in full compliance with any court
21 ordered criminal probation, payments, and other orders.

22 11. QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations
23 under penalty of perjury on forms provided by the Board, stating whether there has been
24 compliance with all the conditions of probation.

25 Respondent shall submit quarterly declarations not later than 10 calendar days after the end
26 of the preceding quarter.

27 12. GENERAL PROBATION REQUIREMENTS.

28 Compliance with Probation Unit

1 Respondent shall comply with the Board's probation unit.

2 Address Changes

3 Respondent shall, at all times, keep the Board informed of Respondent's business and
4 residence addresses, email address (if available), and telephone number. Changes of such
5 addresses shall be immediately communicated in writing to the Board or its designee. Under no
6 circumstances shall a post office box serve as an address of record, except as allowed by Business
7 and Professions Code section 2021, subdivision (b).

8 Place of Practice

9 Respondent shall not engage in the practice of medicine in Respondent's or patient's place
10 of residence, unless the patient resides in a skilled nursing facility or other similar licensed
11 facility.

12 License Renewal

13 Respondent shall maintain a current and renewed California physician's and surgeon's
14 license.

15 Travel or Residence Outside California

16 Respondent shall immediately inform the Board or its designee, in writing, of travel to any
17 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty
18 (30) calendar days.

19 In the event Respondent should leave the State of California to reside or to practice
20 Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of
21 departure and return.

22 13. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be
23 available in person upon request for interviews either at Respondent's place of business or at the
24 probation unit office, with or without prior notice throughout the term of probation.

25 14. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or
26 its designee in writing within 15 calendar days of any periods of non-practice lasting more than
27 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is
28 defined as any period of time Respondent is not practicing medicine as defined in Business and

1 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct
2 patient care, clinical activity or teaching, or other activity as approved by the Board. If
3 Respondent resides in California and is considered to be in non-practice, Respondent shall
4 comply with all terms and conditions of probation. All time spent in an intensive training
5 program which has been approved by the Board or its designee shall not be considered non-
6 practice and does not relieve Respondent from complying with all the terms and conditions of
7 probation. Practicing medicine in another state of the United States or Federal jurisdiction while
8 on probation with the medical licensing authority of that state or jurisdiction shall not be
9 considered non-practice. A Board-ordered suspension of practice shall not be considered as a
10 period of non-practice.

11 In the event Respondent's period of non-practice while on probation exceeds 18 calendar
12 months, Respondent shall successfully complete the Federation of State Medical Boards's Special
13 Purpose Examination, or, at the Board's discretion, a clinical competence assessment program
14 that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model
15 Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

16 Respondent's period of non-practice while on probation shall not exceed two (2) years.

17 Periods of non-practice will not apply to the reduction of the probationary term.

18 Periods of non-practice for a Respondent residing outside of California will relieve
19 Respondent of the responsibility to comply with the probationary terms and conditions with the
20 exception of this condition and the following terms and conditions of probation: Obey All Laws;
21 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
22 Controlled Substances; and Biological Fluid Testing..

23 15. COMPLETION OF PROBATION. Respondent shall comply with all financial
24 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the
25 completion of probation. Upon successful completion of probation, Respondent's certificate shall
26 be fully restored.

27 16. VIOLATION OF PROBATION. Failure to fully comply with any term or condition
28 of probation is a violation of probation. If Respondent violates probation in any respect, the

1 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and
2 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,
3 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have
4 continuing jurisdiction until the matter is final, and the period of probation shall be extended until
5 the matter is final.

6 17. LICENSE SURRENDER. Following the effective date of this Decision, if
7 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
8 the terms and conditions of probation, Respondent may request to surrender his or her license.
9 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in
10 determining whether or not to grant the request, or to take any other action deemed appropriate
11 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
12 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its
13 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject
14 to the terms and conditions of probation. If Respondent re-applies for a medical license, the
15 application shall be treated as a petition for reinstatement of a revoked certificate.

16 18. PROBATION MONITORING COSTS. Respondent shall pay the costs associated
17 with probation monitoring each and every year of probation, as designated by the Board, which
18 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of
19 California and delivered to the Board or its designee no later than January 31 of each calendar
20 year.

21 19. FUTURE ADMISSIONS CLAUSE. If Respondent should ever apply or reapply for
22 a new license or certification, or petition for reinstatement of a license, by any other health care
23 licensing action agency in the State of California, all of the charges and allegations contained in
24 Accusation No. 800-2018-042937 shall be deemed to be true, correct, and admitted by
25 Respondent for the purpose of any Statement of Issues or any other proceeding seeking to deny or
26 restrict license.


27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Peter R. Osinoff, Esq. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: 12/29/21 
ADELINA VORPERIAN, M.D.
Respondent

I have read and fully discussed with Respondent Adelina Vorperian, M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: 12/30/2021 
PETER R. OSINOFF, ESQ.
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: 12/30/21 Respectfully submitted,


ROB BONTA
Attorney General of California
JUDITH T. ALVARADO
Supervising Deputy Attorney General

TAN N. TRAN
Deputy Attorney General
Attorneys for Complainant

Exhibit A

Accusation No. 800-2018-042937

1 XAVIER BECERRA
Attorney General of California
2 JUDITH T. ALVARADO
Supervising Deputy Attorney General
3 EDWARD KIM
Deputy Attorney General
4 State Bar No. 195729
California Department of Justice
5 300 So. Spring Street, Suite 1702
Los Angeles, CA 90013
6 Telephone: (213) 269-6000
Facsimile: (916) 731-2117
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **MEDICAL BOARD OF CALIFORNIA**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2018-042937

13 **ADELINA VORPERIAN, M.D.**
7341 Foothill Blvd., Ste. 203
Tujunga, CA 91042-2720

ACCUSATION

14 **Physician's and Surgeon's**
15 **Certificate No. C 50390,**

16 Respondent

17 **PARTIES**

18 1. William Prasifka (Complainant) brings this Accusation solely in his official capacity
19 as the Executive Director of the Medical Board of California, Department of Consumer Affairs
20 (Board).

21 2. On or about March 24, 2000, the Medical Board issued Physician's and Surgeon's
22 Certificate Number C 50390 to Adelina Vorperian, M.D. (Respondent). The Physician's and
23 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought
24 herein and will expire on June 30, 2021, unless renewed.

25 **JURISDICTION**

26 3. This Accusation is brought before the Board, under the authority of the following
27 laws. All section references are to the Business and Professions Code (Code) unless otherwise
28 indicated.

1 STATUTORY PROVISIONS

2 4. Section 2227 of the Code provides that a licensee who is found guilty under the
3 Medical Practice Act may have his or her license revoked, suspended for a period not to exceed
4 one year, placed on probation and required to pay the costs of probation monitoring, or such other
5 action taken in relation to discipline as the Board deems proper.

6 5. Section 2234 of the Code, states:

7 The board shall take action against any licensee who is charged with
8 unprofessional conduct. In addition to other provisions of this article, unprofessional
conduct includes, but is not limited to, the following:

9 (a) Violating or attempting to violate, directly or indirectly, assisting in or
10 abetting the violation of, or conspiring to violate any provision of this chapter.

11 (b) Gross negligence.

12 (c) Repeated negligent acts. To be repeated, there must be two or more
13 negligent acts or omissions. An initial negligent act or omission followed by a
separate and distinct departure from the applicable standard of care shall constitute
repeated negligent acts.

14 (1) An initial negligent diagnosis followed by an act or omission medically
15 appropriate for that negligent diagnosis of the patient shall constitute a single
negligent act.

16 (2) When the standard of care requires a change in the diagnosis, act, or
17 omission that constitutes the negligent act described in paragraph (1), including, but
not limited to, a reevaluation of the diagnosis or a change in treatment, and the
18 licensee's conduct departs from the applicable standard of care, each departure
constitutes a separate and distinct breach of the standard of care.

19 (d) Incompetence.

20 (e) The commission of any act involving dishonesty or corruption that is
21 substantially related to the qualifications, functions, or duties of a physician and
surgeon.

22 (f) Any action or conduct that would have warranted the denial of a certificate.

23 (g) The failure by a certificate holder, in the absence of good cause, to attend
24 and participate in an interview by the board. This subdivision shall only apply to a
certificate holder who is the subject of an investigation by the board.

25 6. Section 2266 of the Code states: The failure of a physician and surgeon to maintain
26 adequate and accurate records relating to the provision of services to their patients constitutes
27 unprofessional conduct.

28 ///

1 FIRST CAUSE FOR DISCIPLINE

2 (Gross Negligence, Repeated Negligent Acts and Inadequate Record Keeping)

3 Patient A¹

4 7. Respondent Adelina Vorperian, M.D. is subject to disciplinary action under Code
5 sections 2234, subdivisions (b) and (c) and 2266, in that Respondent committed gross negligence,
6 repeated negligent acts and failed to maintain adequate and/or accurate records related to the
7 provision of medical services to Patient A. The circumstances are as follows:

8 8. On or about June 11, 2020, representatives of the Board interviewed Respondent
9 (hereinafter, the "Subject Interview") about her care for the patients alleged herein. At her
10 Subject Interview, Respondent stated that on or about December 7, 2012, Patient A, a 49-year-old
11 woman, presented to Respondent's office with back pain from a motor vehicle accident she had in
12 1999. Respondent continued to see Patient A and prescribe Suboxone² to her, despite being
13 aware that other providers had prescribed Soma³ and Xanax⁴ to Patient A. Respondent also
14 recognized that Patient A was a difficult patient, who did not follow rules. A CURES⁵ report
15 showed that in 2018 Respondent regularly prescribed Suboxone to Patient A and that another
16 physician regularly prescribed alprazolam⁶ and Soma to Patient A. Documentation indicated that

17 _____
18 ¹ The patients' identities are known to Respondent. A letter here is used in lieu of the
19 patients' names in order to address privacy concerns.

20 ² "Suboxone" is a brand name of a form of buprenorphine which is an opioid medication
21 used to treat opioid addiction. It is a semi-synthetic opioid derived from thebain. It is a Schedule
22 V controlled substance pursuant to Health and Safety Code section 11058, subdivision (d), and a
23 dangerous drug pursuant to Business and Professions Code section 4022.

24 ³ "Soma" is a trade name for carisoprodol. It is a muscle-relaxant and sedative. It is a
25 Schedule IV controlled substance pursuant to federal Controlled Substances Act, and a dangerous
26 drug pursuant to Business and Professions Code section 4022.

27 ⁴ See alprazolam.

28 ⁵ The Controlled Substance Utilization Review and Evaluation System (CURES),
maintained by the Department of Justice is an electronic database that tracks all Schedule II – IV
controlled substances dispensed to patients in California.

⁶ "Alprazolam" is a benzodiazepine drug used to treat anxiety disorders, panic disorders,
and anxiety caused by depression. Alprazolam has a central nervous system depressant effect and
patients should be cautioned about the simultaneous ingestions of alcohol and other central
nervous system depressant drugs during treatment with it. Addiction prone individuals (such as
drug addicts or alcoholics) should be under careful surveillance when receiving alprazolam
because of the predisposition of such patients to habituation and dependence. The usual starting
dose of alprazolam is 0.25 mg to 0.5 mg, three times per day (for a maximum 1.5 mg per day). It
is also sold under various brand names including, Intensol®, Xanax®, and Xanax XR®. It is a

1 Health Net Pharmaceutical Services approved Suboxone prescriptions for Patient A from May
2 2017 to June 2019.

3 9. On or about August 13, 2015, Respondent saw Patient A for a follow up visit
4 regarding the patient's Suboxone maintenance program for her opioid addiction, and documented
5 the patient's muscle spasms.

6 10. During her Subject Interview, when questioned about her visit with Patient A on or
7 about April 17, 2017, Respondent read her documentation for the visit which stated that the
8 patient received Suboxone and Soma. On or about September 5, 2017, Respondent increased
9 Patient A's dose of Suboxone from one 8-2 SL, bid to one and a half, bid after a request from the
10 patient for an increase. The subjective history for that visit stated cramps are increased, getting
11 divorced, and very emotional. No other additional history or physical finding validated the
12 increased prescription for Suboxone. When questioned about her visit with Patient A on or about
13 November 15, 2018, Respondent read her documentation for the visit which indicated that
14 Patient A was being treated with Xanax by her psychiatrist. When questioned about her visit with
15 Patient A on or about March 12, 2019, Respondent read her documentation for the visit which
16 indicated that Patient A was being treated with Xanax by her psychiatrist and Soma by her
17 orthopedist and Suboxone by Respondent. She then stated that she repeatedly told the patient not
18 to take sedating medications with Suboxone, but the patient did not follow her instructions.⁷
19 Nonetheless, prior to discharging her from her clinic in March 2019, Respondent failed to taper or
20 discontinue Suboxone for Patient A.

21 11. During her Subject Interview, Respondent stated that she performs random and
22 routine urine drug testing in her office. However, prior to approximately June of 2018,
23 Respondent's urine drug screen testing did not test for Suboxone. Although her documentation

24 _____
25 schedule IV controlled substance pursuant to Health and Safety Code section 11057(d)(1), and a
26 dangerous drug as defined in Business and Professions code section 4022. It is also a Schedule
27 IV controlled substance as defined by the Code of Federal Regulations Title 21, section 1308.14
28 (c).

⁷ Combining drugs such as opioids, benzodiazepines and Soma/carisoprodol (a muscle
relaxant) can result in severe respiratory depression and even death. These combinations pose an
extremely high risk of abuse or addiction as well.

1 indicated multiple entries for urine drug screens for Patient A, there is only one documented
2 result dated August 29, 2019, which indicated that the result was negative for opioids.

3 12. In or around August 2015 and thereafter, each of the following acts or omissions by
4 Respondent constitutes gross negligence:

5 (a) When she prescribed Suboxone to Patient A, including⁸ when the patient was
6 prescribed alprazolam and Soma during the same time period;

7 (b) When she failed to taper or discontinue Suboxone, including when the patient was
8 concurrently taking alprazolam and Soma;

9 (c) When she prescribed doses of Suboxone without documenting new information about
10 the cause of Patient A's pain;

11 (d) When she failed to adequately screen Patient A for drug use and/or document the
12 results of routine urine drug screens for Patient A, including screens for Suboxone.

13 13. In or around 2014 and thereafter, Respondent's overall management of Patient A's
14 chronic pain condition with controlled substances represents gross negligence. Respondent failed
15 to adequately perform and/or document a history and physical examination of Patient A, while
16 continuously prescribing controlled substances to the patient.

17 14. In or around 2014 and thereafter, Respondent committed negligence when she failed
18 to accurately and/or adequately document her care and treatment for Patient A, including in
19 respect of the results of any other treatment modalities, including physical therapy, for Patient A.
20 Although Respondent documented physical therapy in her notes for Patient A, she failed to
21 adequately document the results of Patient A's physical therapy sessions.

22 15. In or around 2014 and thereafter, Respondent committed negligence in connection
23 with Patient A by failing to use standard guidelines in the use of controlled substances for a
24 patient with chronic pain and/or failing to maintain accurate and/or adequate medical records for
25 Patient A, including in respect of her use of controlled substances. Respondent's record for
26 Patient A failed to document a rationale for medication changes, or periodic reviews of the
27 patient's treatment plan.

28 ⁸ As used herein, "including," means "including, without limitation."

1 SECOND CAUSE FOR DISCIPLINE

2 (Gross Negligence, Repeated Negligent Acts and Inadequate Record Keeping)

3 Patient B

4 16. Respondent Adelina Vorperian, M.D. is subject to disciplinary action under Code
5 sections 2234, subdivisions (b) and (c) and 2266, in that Respondent committed gross negligence,
6 repeated negligent acts and failed to maintain adequate and/or accurate records related to the
7 provision of medical services to Patient B. The circumstances are as follows:

8 17. On or about December 29, 2014, Respondent saw Patient B, a 27-year-old man, with
9 a chief complaint of an opioid addiction. He had a history of taking heroin,⁹ oxycodone,¹⁰
10 Dilaudid¹¹ and Suboxone. He had been currently taking Xanax. When asked about this visit at
11 her Subject Interview, Respondent stated that she believed she should not deprive a patient from
12 "benzos"¹² if they are on Suboxone because they can have seizures, and therefore maintained the

13 ⁹ Heroin is a highly addictive drug made from morphine.

14 ¹⁰ Oxycodone is an opioid analgesic medication synthesized from thebaine. It is a semi-
15 synthetic narcotic analgesic with multiple actions quantitatively similar to those of morphine. It
16 is generally used as an analgesic, but it also has a high potential for abuse. Repeated
17 administration of oxycodone may result in psychic and physical dependence. Oxycodone is
18 commonly prescribed for moderate to severe chronic pain. It is sold in its various forms under
19 several brand names, including OxyContin (a time-release formula) and Roxicodone.
20 Oxycodone is also available in combination with acetaminophen (Endocet, Percocet, Roxicet,
21 Tylox, others); aspirin (Endodan, Percodan, Roxiprin, others); and ibuprofen (Combunox). It is a
22 Schedule II controlled substance pursuant to Health and Safety Code section 11055, subdivision
(b)(1)(M), and a dangerous drug as defined in Business and Professions Code section 4022.

23 ¹¹ Dilaudid¹¹ is a brand name for hydromorphone, a Schedule II controlled substance as
24 designated by Health and Safety Code section 11055, subdivision (b)(1)(K), and a dangerous drug
25 as designated in Health and Safety Code section 4022. Hydromorphone is an opioid pain
26 medication used to treat moderate to severe pain. It has been marketed, in its varying forms,
27 under a number of brand names, including Dilaudid. Hydromorphone is a Schedule II controlled
28 substance pursuant to Health and Safety Code section 11055, subdivision (b)(1)(J), and a
dangerous drug pursuant to Business and Professions Code section 4022.

¹² "Benzodiazepines" are a class of drugs that produce central nervous system (CNS)
depression. They are used therapeutically to produce sedation, induce sleep, relieve anxiety and
muscle spasms, and to prevent seizures. They are most commonly used to treat insomnia and
anxiety. In general, benzodiazepines act as hypnotics in high doses, anxiolytics in moderate
doses, and sedatives in low doses. There is the potential for dependence on and abuse of
benzodiazepines particularly by individuals with a history of multi-substance abuse.
Benzodiazepines can cause dangerous deep unconsciousness. When combined with other CNS
depressants such as alcoholic drinks and opioids, the potential for toxicity and fatal overdose
increases. Benzodiazepines are commonly misused and taken in combination with other drugs of
abuse. Alprazolam (Xanax®), lorazepam (Ativan®), clonazepam (Klonopin®), diazepam
(Valium®), and temazepam (Restoril®) are among the most prescribed, as well as the most
frequently encountered benzodiazepines on the illicit market. Benzodiazepines are generally used

1 patient on Xanax because of his long history of anxiety. Respondent also stated that the patient
2 "looked normal" and was much more responsible than Patient A.

3 18. When questioned about a prescription the patient filled from another doctor for
4 methadone¹³ on or about June 19, 2015, and Respondent's prescription for Suboxone to the
5 patient filled only seven days later, Respondent stated that she was not aware of this fact and that
6 the doctor who prescribed the methadone "is stupid" because the patient could have overdosed
7 and died from it. When asked if she would have done anything differently if she had been aware
8 that the patient was receiving methadone, Respondent replied that she would not change anything
9 but would have advised Patient B not to take it. She also admitted to prescribing Xanax to Patient
10 B as well, but that she did not check CURES during that time period.

11 19. On or about December 29, 2016, Respondent saw Patient B and changed the patient's
12 prescription for Xanax to Klonopin.¹⁴ However, within a few months, she switched the
13 prescription for Klonopin back to Xanax.

14 20. CURES records for Patient B reflect that the patient filled prescriptions for
15 methadone and clonazepam¹⁵ on or about June 19, 2015 and July 28, 2015 from another provider.
16 At the Subject Interview, Respondent stated that she performed a urine drug screen for Patient B
17 on or about June 18, 2015 and the results did not indicate any opiates in his urine. Urine drug
18 screen results in a note dated March 26, 2016 stated "neg for opioid, + for benzo's." Urine drug
19 screen results on an actual urine drug screen form dated December 3, 2015 visit stated "neg for

20 for a limited time period and daily use should only be attempted after other approaches are
21 unsuccessful, and with continuing attention to tapering and discontinuance. Prescribed
22 benzodiazepines should be discussed with the patient (and those patient interactions should be
23 documented), including that they entail: 1) risk of tolerance and dependence, 2) potential
24 interactions with alcohol and pain medications, and 3) possible impairment of driving.

25 ¹³ "Methadone," sold under the brand names Dolophine and Methadose among others, is
26 an opioid used for opioid maintenance therapy in opioid dependence and for chronic pain
27 management. It is a Schedule II controlled substance pursuant to Health and Safety Code section
28 11055, subdivision (c), and a dangerous drug pursuant to Business and Professions Code section
4022.

¹⁴ "Klonopin" is a brand name for clonazepam, which is a medication used to prevent and
treat seizures, panic disorder, and the movement disorder known as akathisia.

¹⁵ Clonazepam is a benzodiazepine-based sedative. It is generally used to control seizures
and panic disorder. It is a Schedule IV controlled substance pursuant to Health and Safety Code
section 11057, subdivision (d)(7), and a dangerous drug as defined in Business and Professions
Code section 4022.

1 opioids, positive for benzo's." Respondent stated that her drug screen testing prior to 2018 did
2 not test for Suboxone and only for opiates. Methadone would not be detected in an opiate screen.
3 Patient B also received a prescription for buprenorphine¹⁶ from another provider on or about June
4 27, 2015 and clonazepam on or about July 28, 2015.

5 21. Respondent also stated that she was aware that Patient B was followed by a
6 psychiatrist, but prescribed benzodiazepines to Patient B for convenience. A CURES report
7 indicated Patient B had filled multiple buprenorphine prescriptions from a different provider for
8 the time period from on or about June 27, 2015 to October 1, 2015, and had filled multiple
9 Suboxone prescriptions from a different provider on or about January 9, 2016, January 12, 2016,
10 and February 7, 2016.

11 22. On or about December 29, 2014 and thereafter, each of the following acts or
12 omissions by Respondent constitutes gross negligence:

13 (a) When she continued to prescribe Suboxone to Patient B while the patient was
14 concomitantly being prescribed other controlled substances, including alprazolam and/or
15 methadone. Respondent concomitantly prescribed Suboxone and alprazolam. She was also
16 aware that the concomitant use of Suboxone, benzodiazepines and/or methadone could result in
17 respiratory depression, coma or death.

18 (b) When she failed to adequately periodically monitor and/or investigate whether Patient
19 B was being prescribed controlled substances by other providers, including through the use of
20 available prescription data.

21 (c) When she failed to adequately provide drug testing for Suboxone and/or methadone.

22 23. On or about December 29, 2014 and thereafter, Respondent's overall management of
23 Patient B's health (including his opiate use disorder and general anxiety disorder) with controlled
24 substances represents gross negligence. Respondent failed to adequately perform and/or
25 document a history and physical examination of Patient B, while continuously prescribing
26 controlled substances to the patient.

27 ///

28 ¹⁶ See Suboxone.

1 24. On or about December 29, 2014 and thereafter, Respondent committed negligence
2 when she failed to adequately perform and/or document periodic reviews of her treatment plan for
3 Patient B.

4 **THIRD CAUSE FOR DISCIPLINE**

5 **(Gross Negligence, Repeated Negligent Acts and Inadequate Record Keeping)**

6 **Patient C**

7 25. Respondent Adelina Vorperian, M.D. is subject to disciplinary action under Code
8 sections 2234, subdivisions (b) and (c) and 2266, in that Respondent committed gross negligence,
9 repeated negligent acts and failed to maintain adequate and/or accurate records related to the
10 provision of medical services to Patient C. The circumstances are as follows:

11 26. On or about October 20, 2016, Respondent saw Patient C, a 31-year-old man, with a
12 chief complaint of an opioid addiction and a desire to quit consuming opioids. He had a history
13 of heroin use for five years. His prescriptions included Klonopin, Lexapro,¹⁷ Baclofen,¹⁸ Lyrica¹⁹
14 and Suboxone. Patient C also had a diagnosis of depression with anxiety, and possibly ulcerative
15 colitis. For a time, he was under the care of a psychiatrist and a gastroenterologist. Respondent
16 continued to see Patient C until on or about April 19, 2019. During her Subject Interview,
17 Respondent stated that the indication for prescribing Suboxone was opiate addiction.

18 27. On or about February 1, 2018, Respondent had prescribed Phenergan,²⁰ Clonazepam

19
20 ¹⁷ Escitalopram is included in the class of drugs called selective serotonin reuptake
21 inhibitors (SSRIs). This class of drugs is used to treat depression, anxiety, and other mood
22 disorders. Escitalopram is mainly used to treat major depressive disorder or generalized anxiety
23 disorder. It is sold under the brand names, Ciprallex® and Lexapro®, among others. It is a
24 dangerous drug as defined in Business and Professions code section 4022.

25 ¹⁸ Baclofen is a muscle relaxer used for treating spasm of skeletal muscles, muscle clonus,
26 rigidity, and pain caused by disorders such as multiple sclerosis. It is also injected into the spinal
27 cord (intrathecal) for management of severe spasticity.

28 ¹⁹ Lyrica is a brand name for pregabalin a nerve pain medication used to treat nerve and
muscle pain, including fibromyalgia. It can also be used to treat seizures. It is a dangerous drug
pursuant to Business and Professions Code section 4022.

²⁰ "Promethazine with codeine" or codeine phosphate/promethazine hydrochloride is an
antihistamine and opioid antitussive combination drug. The combination of an opiate agonist
with antitussive activity (codeine) and a phenothiazine-structure antihistamine (promethazine)
when used together can be prescribed to relieve cough and upper respiratory symptoms due to
conditions such as the common cold. Promethazine is sold in its various forms under the trade
names Phenadoz, Promethegan, and Phenergan. It is a dangerous drug as defined in Business and
Professions Code section 4022.

1 and Suboxone, concomitantly. The results of a urine drug screen on the same day was positive
2 for benzodiazepines, but negative for opiates.

3 28. On or about March 29, 2018, Respondent documented that the patient had chronic
4 nausea controlled with Phenergan.

5 29. On or about October 20, 2016 and thereafter, each of the following acts or omissions
6 by Respondent constitutes gross negligence:

7 (a) When she concurrently prescribed Suboxone and clonazepam to Patient C.

8 (b) When she concurrently prescribed Suboxone and clonazepam and the patient was also
9 prescribed Phenergan. The concomitant use of these drugs could result in respiratory depression,
10 coma or death.

11 (c) When she failed to adequately periodically monitor and/or investigate whether Patient
12 C was being prescribed other controlled substances by other providers, including through the use
13 of available prescription data, including CURES data.

14 (d) When she failed to adequately provide drug testing for Suboxone.

15 30. On or about December 29, 2014 and thereafter, Respondent's overall management of
16 Patient C's health (including his opioid addiction and depression with anxiety) with controlled
17 substances represents gross negligence.

18 31. On or about December 29, 2014 and thereafter, Respondent committed negligence
19 when she failed to adequately perform and/or document periodic reviews of her treatment plan for
20 Patient C.

21 **FOURTH CAUSE FOR DISCIPLINE**

22 **(Repeated Negligent Acts)**

23 32. Respondent is subject to disciplinary action under Code section 2234, subdivision (c),
24 in that Respondent committed repeated negligent acts. The circumstances are as follows:

25 33. The allegations of the First, Second and Third Causes for Discipline are incorporated
26 herein by reference as if fully set forth.

27 34. Each of the alleged acts of gross negligence set forth above is also a negligent act.

28 ///

1 **FIFTH CAUSE FOR DISCIPLINE**

2 **(Failure to Maintain Adequate Medical Records)**

3 35. Respondent is subject to disciplinary action under Code section 2266, in that
4 Respondent failed to maintain adequate and accurate records related to the provision of medical
5 services to a patient. The circumstances are as follows:

6 36. The allegations of the First, Second, Third and Fourth Causes for Discipline,
7 inclusive, are incorporated herein by reference as if fully set forth.

8 **SIXTH CAUSE FOR DISCIPLINE**

9 **(General Unprofessional Conduct)**

10 37. Respondent is subject to disciplinary action under Code section 2234, in that her
11 actions and/or omissions represent unprofessional conduct, generally. The circumstances are as
12 follows:

13 38. The allegations of the First, Second, Third, Fourth and Fifth Causes for Discipline,
14 inclusive, are incorporated herein by reference as if fully set forth.

15 **DISCIPLINARY CONSIDERATIONS**

16 39. To determine the degree of discipline, if any, to be imposed on Respondent,
17 Complainant alleges as follows:

18 40. On or about December 6, 2010, effective January 5, 2011, in a prior action titled *In*
19 *the Matter of the Petition for Termination of Probation of Adelina Vorperian, M.D.* before the
20 Medical Board of California, in case number 26-2009-200756, Respondent's petition to terminate
21 her probation was denied and included factual findings that during an interview by the Board's
22 investigator and during the hearing, Respondent sought to disclaim responsibility for her criminal
23 acts and portrayed herself as a victim; she claimed she did not know that receiving payments for
24 referring specimens to Southwest Labs was wrong, despite her admissions to the contrary in her
25 plea agreement and in the Stipulated Settlement and Disciplinary Order; she suggested that
26 accepting payments for referrals was the way business was done in the Middle East and Africa,
27 where she lived in the past; she further claimed that the representative from the laboratory
28 "frame[d]" her; and when the Board's investigator asked her to consider what she would do

1 differently, she mentioned that she would not have moved to California, rather than anything
2 about not accepting the illegal payments; she decried her suffering and the unbelievable nature of
3 her situation and contended that she "didn't harm anybody" through her crimes. That decision is
4 now final and is incorporated by reference as if fully set forth herein.

5 41. On or about September 21, 2012, effective October 19, 2012, in a prior disciplinary
6 action titled *In the Matter of the Accusation and Petition to Revoke Probation Against Adelina*
7 *Vorperian, M.D.* before the Medical Board of California, in case number D1-2005-168275,
8 Respondent's license was placed on probation for 5 years with terms and conditions, in
9 connection with aiding and abetting the unlicensed practice of medicine and violating the terms of
10 her probation including, failure to obey all laws and failure to submit quarterly declarations and
11 update her business address stating/disclosing her involvement in a clinic as medical director.
12 That decision is now final and is incorporated by reference as if fully set forth herein.

13 42. On or about July 25, 2005, in a prior criminal proceeding in United States District
14 Court (Central District of California) case number CR-05-441, Respondent was convicted of two
15 counts of violating 42 United States Code sections 1320a, for receiving illegal kickbacks from a
16 laboratory, located in Glendale, California. The record of that conviction from that criminal
17 proceeding is incorporated as if fully set forth.

18 43. On or about October 27, 2006, effective November 27, 2006, in a prior disciplinary
19 action titled *In the Matter of the Accusation Against Adelina Vorperian, M.D.* before the Medical
20 Board of California, in case number 11-2005-168275, Respondent's license was placed on
21 probation for 5 years with terms and conditions, in connection with suffering a conviction of a
22 crime in connection with her involvement in a kickback relationship with a clinical laboratory
23 (i.e. soliciting and receiving remuneration in the form of cash kickbacks from Southwest Labs in
24 return for ordering a service. That decision is now final and is incorporated by reference as if
25 fully set forth herein.

26 ///

27 ///

28 ///


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate Number C 50390, issued to Adelina Vorperian, M.D.;
2. Revoking, suspending or denying approval of Adelina Vorperian, M.D.'s authority to supervise physician assistants and advanced practice nurses;
3. Ordering Adelina Vorperian, M.D., if placed on probation, to pay the Board the costs of probation monitoring; and
4. Taking such other and further action as deemed necessary and proper.

DATED: JAN 25 2021



WILLIAM PRASIPKA
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

LA2020603418
63887050.docx